Pfizer Annual Revenue Doubled – to $81.3 Billion – Thanks to COVID Vaccines

Joseph Mercola

The COVID-19 pandemic has been a real boon to Pfizer. Not only has it doubled Pfizer’s annual revenue, but it has also given the drugmaker unique weight in determining U.S. health policy …

Pfizer’s COVID jab dominates 70% of the U.S. and European markets, and Paxlovid, its COVID drug, has become a standard treatment choice in hospitals. This despite findings showing the shot doesn’t prevent infection or transmission, and that Paxlovid causes severe rebound and supercharges mutations.

… Pfizer’s contracts are almost exclusively slanted in Pfizer’s favor. They’re guaranteed payment while having no financial liability for injuries and deaths, and it appears this indemnification applies even if they were to be found guilty of fraud.

Latest articles

The Goddard Report A podcast with Dr. Stephen Malthouse on “Making Doctors... All previous outbreaks, epidemics and pandemics end when Community Immunity, NOT...
Amanuensis Variants have been one of the hallmarks of this pandemic, with...
Samuel Reinfeld et al. The COVID-19 pandemic continues to have a deleterious...

Thank you!

Thank you for your membership application. As soon as your payment has been received your membership will be activated and you will be informed via email.

Thank you.

Thank you!

The form has been submitted successfully!